Surprisingly, although treatment with scVEGF/177Lu is clearly anti-angiogenic, unlike other anti-angiogenic drugs, it appears to decrease the prevalence of CD206-positive M2-type TAMs in primary tumor (Fig. 6) and metastatic lesions in the kidney (Additional file 4: Figure S4). The gene discussed is MRC1; the disease is neoplasm.